Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Apostolopoulos, Neoklis; Mayer, Ursula

doi:10.1002/vrc2.13

Cited by 4 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two previously reported case reports of Hymenoptera hypersensitivity utilised a canine-validated European laboratory that had facilities to perform CCD inhibition assays (ELISA; Fcε-Receptor technology; Laboklin GmbH & Co. KG). 11,23 Access to this laboratory was cost-prohibitive as a consequence of the author's geographical location.…”

Section: Discussionmentioning

confidence: 99%

“…The laboratory used in this study could not perform CCD inhibition assays and thus we could not determine the role of CCDs in accounting for the false‐positive sIgE results. Two previously reported case reports of Hymenoptera hypersensitivity utilised a canine‐validated European laboratory that had facilities to perform CCD inhibition assays (ELISA; Fcε‐Receptor technology; Laboklin GmbH & Co. KG) 11,23 . Access to this laboratory was cost‐prohibitive as a consequence of the author's geographical location.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sensitivity of a Hymenoptera serological immunoglobulin (Ig)E assay for the diagnosis of venom hypersensitivity in dogs

Chan

Burrows

Hosgood

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

BackgroundHymenoptera envenomation with honey bee (Apis mellifera) and paper wasp (Polistes spp.) may cause life‐threatening anaphylaxis in dogs. In human patients, clinical history, intradermal testing (IDT) and measurement of allergen‐specific serological immunoglobulin (Ig)E (sIgE) are used to support a diagnosis of Hymenoptera venom hypersensitivity. The utility of venom allergen‐specific sIgE has not yet been evaluated for this purpose in dogs.ObjectivesThe objective of the study was to investigate the sensitivity (sn), specificity (sp) and positive predictive value (PPV) of honey bee and paper wasp serological titres using a commercially available sIgE assay [VARL (Veterinary Allergen Reference Laboratory) Liquid Gold] against clinical history for a diagnosis of Hymenoptera hypersensitivity in dogs.Materials and MethodsHoneybee and paper wasp IgE serum titres were measured in 15 client‐owned dogs with a diagnosis of Hymenoptera venom hypersensitivity based on a history of anaphylaxis, owner observation of Hymenoptera, and positive IDT to bee and/or wasp; and in 10 client‐owned dogs with no known history of anaphylaxis or Hymenoptera exposure and a negative IDT to bee and wasp.ResultsAnalysis of receiver operating characteristic (ROC) curves demonstrate that a VARL score cut‐off of one of six for honeybee yields Sn, Sp and PPV of 40%, 60% and 60%, respectively, and two of six for wasp yields Sn, Sp and PPV of 25%, 78% and 60%, respectively.Conclusions and Clinical RelevanceOwing to the poor sensitivity and PPV of sIgE assays for both bee and wasp hypersensitivity in dogs with known envenomation and anaphylaxis, the use of sIgE cannot be recommended as a tool for venom identification.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sensitivity of a Hymenoptera serological immunoglobulin (Ig)E assay for the diagnosis of venom hypersensitivity in dogs

Chan

Burrows

Hosgood

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…One publication reported that the majority of adverse reactions to VIT in dogs were mild and infrequent, occurring in 2.8% of 1944 venom injections administered during induction and maintenance VIT in 82 dogs 10 . Single case reports of dogs receiving VIT for 5 years and 2.9 years, respectively, report no adverse reactions 12,13 …”

Section: Introductionmentioning

confidence: 99%

“…10 Single case reports of dogs receiving VIT for 5 years and 2.9 years, respectively, report no adverse reactions. 12,13 The objective of this study was to evaluate the safety of a modified rush VIT protocol in dogs as determined by the frequency and severity of adverse reactions. We hypothesised that rush VIT would be safe in dogs, with a low frequency of adverse reactions.…”

Section: Introductionmentioning

confidence: 99%

Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity

Moore

Burrows

Rosenkrantz³

et al. 2023

Veterinary Dermatology

View full text Add to dashboard Cite

BackgroundHymenoptera envenomation occurs frequently in people and dogs and can trigger anaphylaxis. Venom immunotherapy (VIT) is the only preventive treatment for Hymenoptera hypersensitivity and is indicated for people with severe adverse reactions to insect stings. Rush VIT is an accelerated VIT protocol in people. This has not been reported in dogs.ObjectivesThe objective of the study was to evaluate the safety of modified rush VIT.AnimalsTwenty client‐owned dogs with Hymenoptera hypersensitivity based on a history of adverse reactions to Hymenoptera envenomation and a positive intradermal test to honey bee and/or paper wasp venom.Materials and MethodsDogs received incremental doses of venom via subcutaneous injection one day per week for three consecutive weeks until the maintenance dose was achieved. Vital signs were recorded every 30 min prior to venom administration. Adverse reactions were categorised as localised or grade I–IV systemic reactions.ResultsNineteen of 20 dogs (95%) completed rush VIT. One dog experienced a grade III systemic adverse reaction and was withdrawn from the study. No adverse reactions occurred in 10 of 20 dogs (50%). Localised and grade I–II systemic reactions occurred in nine of 20 dogs (45%), including nausea (n = 5), injection site pruritus (n = 3) and diarrhoea and lethargy (n = 1).Conclusions and Clinical RelevanceModified rush VIT in dogs was well‐tolerated and should be considered for dogs with Hymenoptera hypersensitivity. Larger studies are needed to evaluate the efficacy of VIT in dogs for preventing hypersensitivity reactions to insect stings.

show abstract

“…Therefore, the recommended duration for VIT in humans is 5 years or even life-long in patients with high risk of future bee stings [14,15]. In dogs, it was shown that VIT was well-tolerated in conventional and rush protocols, but prospective controlled trials on the efficacy are missing [3,[17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Rostaher,

Fischer,

Vigani

et al. 2023

Animals

View full text Add to dashboard Cite

Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

show abstract

Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

Cited by 4 publications

References 11 publications

Sensitivity of a Hymenoptera serological immunoglobulin (Ig)E assay for the diagnosis of venom hypersensitivity in dogs

Sensitivity of a Hymenoptera serological immunoglobulin (Ig)E assay for the diagnosis of venom hypersensitivity in dogs

Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity

Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

Contact Info

Product

Resources

About